Article
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
British journal of cancer - 9 Sept 2014
Schneider B P, Li L, Shen F, Miller K D, Radovich M, O'Neill A, Gray R J, Lane D, Flockhart D A, Jiang G, Wang Z, Lai D, Koller D, Pratt J H, Dang C T, Northfelt D, Perez E A, Shenkier T, Cobleigh M, Smith M L, Railey E, Partridge A, Gralow J, Sparano J, Davidson N E, Foroud T, Sledge G W
Abstract excerpt
BACKGROUND: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension. METHODS: A genome-wide association study (GWAS) was performed in the phase III bevacizumab-based adjuvant breast cancer trial, ECOG-5103, to evaluate for an association between genotypes and hypertension. GWAS was conducted in those who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.